| REVENUE | 39.58K |
| Salaries | 4.11M |
| General and administrative expenses | 2.28M |
| Research and development | |
| Stock-based compensation | |
| Patent amortization | |
| TOTAL OPERATING EXPENSES | 19.38M |
| OPERATING LOSS | -19.34M |
| Loss on equity of investments - Nanotope | |
| Gain on sale of stock in subsidiary | |
| Loss on sale of fixed assets, net | 0 |
| Realized and unrealized gain (loss) on marketable securities | |
| Interest income (expense), net | |
| Change in value of derivatives | -113.36K |
| TOTAL OTHER INCOME (EXPENSE) | -79.26K |
| LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | -19.42M |
| Provision for income taxes | |
| LOSS FROM CONTINUING OPERATIONS | |
| Income (loss) from discontinued operations | |
| Gain (loss) on disposal of discontinued operations | |
| NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS | |
| NET INCOME (LOSS) | -19.42M |
| Net (income) loss attributable to noncontrolling interests | |
| NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD | -19.42M |
| Income (loss) from continuing operations attributable to Arrowhead common shareholders | |
| Income from discontinued operations attributable to Arrowhead common shareholders | |
| Net income (loss) attributable to Arrowhead shareholders | |
| Weighted average shares outstanding | |
| Income (loss) from continuing operations attributable to Arrowhead common shareholders | |
| Income from discontinued operations attributable to Arrowhead common shareholders | |
| Net income (loss) attributable to Arrowhead shareholders | |
| Weighted average shares outstanding | |